New antiretroviral drugs: A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir

Christine A. Hughes, Linda Robinson, Alice Tseng, Rodger D. MacArthur

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Background: The introduction and approval of new antiretroviral agents in the US and Canada bring new opportunities and new challenges. Arguably, for the first time ever, clinicians have the drugs necessary to achieve the goal of suppressing HIV RNA to levels less than 50 copies/mL in even the most treatment-experienced patients and in those with extensive drug-limiting resistance mutations. However, the use of these new agents is complicated by many drug-drug interactions and - to some extent - pre-existing mutations. To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical. Objective: To thoroughly review the six most recently approved or soon-to-be-approved antiretroviral drugs in the US and Canada: tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Methods: Discussion of the indications for, and pharmacokinetics, resistance profile, activity, toxicity, and clinical trials results of, the six new agents. Results/conclusions: These six new agents have resulted in marked progress towards the goal of being able to provide HIV-infected individuals with the drugs necessary to achieve decades of durable suppression of HIV without substantial toxicity.

Original languageEnglish (US)
Pages (from-to)2445-2466
Number of pages22
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number15
DOIs
StatePublished - Oct 1 2009

Fingerprint

Rilpivirine
etravirine
Pharmacokinetics
Safety
Pharmaceutical Preparations
HIV
Canada
Anti-Retroviral Agents
Mutation
Drug Interactions
Drug Resistance
tipranavir
Raltegravir Potassium
Darunavir
maraviroc
Clinical Trials
RNA

Keywords

  • Antiretroviral therapy
  • Darunavir
  • Etravirine
  • HIV
  • Maraviroc
  • Raltegravir
  • Rilpivirine
  • Tipranavir

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New antiretroviral drugs : A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. / Hughes, Christine A.; Robinson, Linda; Tseng, Alice; MacArthur, Rodger D.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 15, 01.10.2009, p. 2445-2466.

Research output: Contribution to journalReview article

@article{3ed504861acd49799c13638c92fb7f05,
title = "New antiretroviral drugs: A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir",
abstract = "Background: The introduction and approval of new antiretroviral agents in the US and Canada bring new opportunities and new challenges. Arguably, for the first time ever, clinicians have the drugs necessary to achieve the goal of suppressing HIV RNA to levels less than 50 copies/mL in even the most treatment-experienced patients and in those with extensive drug-limiting resistance mutations. However, the use of these new agents is complicated by many drug-drug interactions and - to some extent - pre-existing mutations. To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical. Objective: To thoroughly review the six most recently approved or soon-to-be-approved antiretroviral drugs in the US and Canada: tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Methods: Discussion of the indications for, and pharmacokinetics, resistance profile, activity, toxicity, and clinical trials results of, the six new agents. Results/conclusions: These six new agents have resulted in marked progress towards the goal of being able to provide HIV-infected individuals with the drugs necessary to achieve decades of durable suppression of HIV without substantial toxicity.",
keywords = "Antiretroviral therapy, Darunavir, Etravirine, HIV, Maraviroc, Raltegravir, Rilpivirine, Tipranavir",
author = "Hughes, {Christine A.} and Linda Robinson and Alice Tseng and MacArthur, {Rodger D.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1517/14656560903176446",
language = "English (US)",
volume = "10",
pages = "2445--2466",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "15",

}

TY - JOUR

T1 - New antiretroviral drugs

T2 - A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir

AU - Hughes, Christine A.

AU - Robinson, Linda

AU - Tseng, Alice

AU - MacArthur, Rodger D.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background: The introduction and approval of new antiretroviral agents in the US and Canada bring new opportunities and new challenges. Arguably, for the first time ever, clinicians have the drugs necessary to achieve the goal of suppressing HIV RNA to levels less than 50 copies/mL in even the most treatment-experienced patients and in those with extensive drug-limiting resistance mutations. However, the use of these new agents is complicated by many drug-drug interactions and - to some extent - pre-existing mutations. To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical. Objective: To thoroughly review the six most recently approved or soon-to-be-approved antiretroviral drugs in the US and Canada: tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Methods: Discussion of the indications for, and pharmacokinetics, resistance profile, activity, toxicity, and clinical trials results of, the six new agents. Results/conclusions: These six new agents have resulted in marked progress towards the goal of being able to provide HIV-infected individuals with the drugs necessary to achieve decades of durable suppression of HIV without substantial toxicity.

AB - Background: The introduction and approval of new antiretroviral agents in the US and Canada bring new opportunities and new challenges. Arguably, for the first time ever, clinicians have the drugs necessary to achieve the goal of suppressing HIV RNA to levels less than 50 copies/mL in even the most treatment-experienced patients and in those with extensive drug-limiting resistance mutations. However, the use of these new agents is complicated by many drug-drug interactions and - to some extent - pre-existing mutations. To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical. Objective: To thoroughly review the six most recently approved or soon-to-be-approved antiretroviral drugs in the US and Canada: tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Methods: Discussion of the indications for, and pharmacokinetics, resistance profile, activity, toxicity, and clinical trials results of, the six new agents. Results/conclusions: These six new agents have resulted in marked progress towards the goal of being able to provide HIV-infected individuals with the drugs necessary to achieve decades of durable suppression of HIV without substantial toxicity.

KW - Antiretroviral therapy

KW - Darunavir

KW - Etravirine

KW - HIV

KW - Maraviroc

KW - Raltegravir

KW - Rilpivirine

KW - Tipranavir

UR - http://www.scopus.com/inward/record.url?scp=70349482329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349482329&partnerID=8YFLogxK

U2 - 10.1517/14656560903176446

DO - 10.1517/14656560903176446

M3 - Review article

C2 - 19678794

AN - SCOPUS:70349482329

VL - 10

SP - 2445

EP - 2466

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -